280 related articles for article (PubMed ID: 23851570)
1. The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys.
Roke Y; van Harten PN; Franke B; Galesloot TE; Boot AM; Buitelaar JK
Pharmacogenet Genomics; 2013 Sep; 23(9):487-93. PubMed ID: 23851570
[TBL] [Abstract][Full Text] [Related]
2. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone.
Roke Y; Buitelaar JK; Boot AM; Tenback D; van Harten PN
J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):432-9. PubMed ID: 23234586
[TBL] [Abstract][Full Text] [Related]
3. Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.
Sukasem C; Hongkaew Y; Ngamsamut N; Puangpetch A; Vanwong N; Chamnanphon M; Chamkrachchangpada B; Sinrachatanant A; Limsila P
J Clin Psychopharmacol; 2016 Apr; 36(2):141-6. PubMed ID: 26872113
[TBL] [Abstract][Full Text] [Related]
4. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism.
Troost PW; Lahuis BE; Hermans MH; Buitelaar JK; van Engeland H; Scahill L; Minderaa RB; Hoekstra PJ
J Clin Psychopharmacol; 2007 Feb; 27(1):52-7. PubMed ID: 17224713
[TBL] [Abstract][Full Text] [Related]
5. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents.
Calarge CA; Ellingrod VL; Acion L; Miller DD; Moline J; Tansey MJ; Schlechte JA
Pharmacogenet Genomics; 2009 May; 19(5):373-82. PubMed ID: 19339912
[TBL] [Abstract][Full Text] [Related]
6. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
[TBL] [Abstract][Full Text] [Related]
7. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia.
Wang L; Yu L; Zhang AP; Fang C; Du J; Gu NF; Qin SY; Feng GY; Li XW; Xing QH; He L
J Psychopharmacol; 2007 Nov; 21(8):837-42. PubMed ID: 17715206
[TBL] [Abstract][Full Text] [Related]
8. Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia.
Charan A; Shewade DG; Rajkumar RP; Chandrasekaran A
Psychiatry Res; 2016 Jun; 240():209-213. PubMed ID: 27111215
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment.
Roke Y; van Harten PN; Buitelaar JK; Tenback DE; Quekel LG; de Rijke YB; Boot AM
Eur J Endocrinol; 2012 Dec; 167(6):855-63. PubMed ID: 23011870
[TBL] [Abstract][Full Text] [Related]
10. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients.
Yasui-Furukori N; Saito M; Tsuchimine S; Nakagami T; Sato Y; Sugawara N; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1491-5. PubMed ID: 18579277
[TBL] [Abstract][Full Text] [Related]
11. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
[TBL] [Abstract][Full Text] [Related]
12. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.
Anderson GM; Scahill L; McCracken JT; McDougle CJ; Aman MG; Tierney E; Arnold LE; Martin A; Katsovich L; Posey DJ; Shah B; Vitiello B
Biol Psychiatry; 2007 Feb; 61(4):545-50. PubMed ID: 16730335
[TBL] [Abstract][Full Text] [Related]
13. Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.
dos Santos Júnior A; Henriques TB; de Mello MP; Ferreira Neto AP; Paes LA; Della Torre OH; Sewaybricker LE; Fontana TS; Celeri EH; Guerra Júnior G; Dalgalarrondo P
J Child Adolesc Psychopharmacol; 2015 Dec; 25(10):738-48. PubMed ID: 26682995
[TBL] [Abstract][Full Text] [Related]
14. Prolactin concentrations during aripiprazole treatment in relation to sex, plasma drugs concentrations and genetic polymorphisms of dopamine D2 receptor and cytochrome P450 2D6 in Japanese patients with schizophrenia.
Nagai G; Mihara K; Nakamura A; Suzuki T; Nemoto K; Kagawa S; Ohta I; Arakaki H; Kondo T
Psychiatry Clin Neurosci; 2012 Oct; 66(6):518-24. PubMed ID: 23066770
[TBL] [Abstract][Full Text] [Related]
15. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele.
Young RM; Lawford BR; Barnes M; Burton SC; Ritchie T; Ward WK; Noble EP
Br J Psychiatry; 2004 Aug; 185():147-51. PubMed ID: 15286066
[TBL] [Abstract][Full Text] [Related]
16. Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.
Calarge CA; Miller del D
J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):163-9. PubMed ID: 21486167
[TBL] [Abstract][Full Text] [Related]
17. The combined effect of CYP2D6 and DRD2 Taq1A polymorphisms on the antipsychotics daily doses and hospital stay duration in schizophrenia inpatients (observational naturalistic study).
Kurylev AA; Brodyansky VM; Andreev BV; Kibitov AO; Limankin OV; Mosolov SN
Psychiatr Danub; 2018 Jun; 30(2):157-163. PubMed ID: 29930225
[TBL] [Abstract][Full Text] [Related]
18. The role of CYP2D6 and TaqI A polymorphisms in malignant neuroleptic syndrome: two case reports with three episodes.
Zivković M; Mihaljević-Peles A; Sagud M; Silić A; Mihanović M
Psychiatr Danub; 2010 Mar; 22(1):112-6. PubMed ID: 20305604
[TBL] [Abstract][Full Text] [Related]
19. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers.
López-Rodríguez R; Román M; Novalbos J; Pelegrina ML; Ochoa D; Abad-Santos F
J Clin Psychopharmacol; 2011 Oct; 31(5):555-62. PubMed ID: 21869700
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects.
Choong E; Polari A; Kamdem RH; Gervasoni N; Spisla C; Jaquenoud Sirot E; Bickel GG; Bondolfi G; Conus P; Eap CB
J Clin Psychopharmacol; 2013 Jun; 33(3):289-98. PubMed ID: 23609392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
